Previous Article | Next Article 
Journal of Clinical Microbiology, April 2008, p. 1418-1425, Vol. 46, No. 4
0095-1137/08/$08.00+0 doi:10.1128/JCM.02168-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
Diagnostic Approach to Acute Diarrheal Illness in a Military Population on Training Exercises in Thailand, a Region of Campylobacter Hyperendemicity
David R. Tribble,1*
Shahida Baqar,1
Lorrin W. Pang,2
Carl Mason,2
Huo-Shu H. Houng,3
Chittima Pitarangsi,2
Carlos Lebron,4
Adam Armstrong,5
Orntipa Sethabutr,2 and
John W. Sanders5
Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland,1
Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand,2
Walter Reed Army Institute of Research, Silver Spring, Maryland,3
Naval Environmental Preventive Medicine Unit 6, Pearl Harbor, Hawaii,4
National Naval Medical Center, Bethesda, Maryland5
Received 8 November 2007/
Returned for modification 1 January 2008/
Accepted 22 January 2008

ABSTRACT
High rates of
Campylobacter fluoroquinolone resistance highlight
the need to evaluate diagnostic strategies that can be used
to assist with clinical management. Diagnostic tests were evaluated
with U.S. soldiers presenting with acute diarrhea during deployment
in Thailand. The results of bedside and field laboratory diagnostic
tests were compared to stool microbiology findings for 182 enrolled
patients.
Campylobacter jejuni was isolated from 62% of the
cases. Clinical and laboratory findings at the time of presentation
were evaluated to determine their impact on the posttest probability,
defined as the likelihood of a diagnosis of
Campylobacter infection.
Clinical findings, the results of tests for inflammation (stool
occult blood testing [Hemoccult], fecal leukocytes, fecal lactoferrin,
plasma C-reactive protein), and the numbers of
Campylobacter-specific
antibody-secreting cells in peripheral blood failed to increase
the posttest probability above 90% in this setting of
Campylobacter hyperendemicity when these findings were present. Positive results
by a
Campylobacter-specific commercial enzyme immunoassay (EIA)
and, less so, a research PCR were strong positive predictors.
The negative predictive value for ruling out
Campylobacter infection,
defined as a posttest probability of less than 10%, was similarly
observed with these
Campylobacter-specific stool-based tests
as well the fecal leukocyte test. Compared to the other tests
evaluated, the
Campylobacter EIA is a sensitive and specific
rapid diagnostic test that may assist with diagnostic evaluation,
with consideration of the epidemiological setting, logistics,
and cost.

INTRODUCTION
Military personnel are frequently affected by short-term morbidity
related to diarrheal diseases, with a potential adverse impact
on the operational mission (
24,
37). The use of empirical therapy
without supplemental laboratory data is a feasible option; however,
refinement of the management strategy by using laboratory testing
may increase the cost-effectiveness and allow specific adjustments
in antibiotic selection on the basis of regional susceptibility
patterns. During military operations, the availability of a
field laboratory with a microbiological testing capability is
variable. Rapid, technically simple diagnostic tests need to
be evaluated to determine their accuracy and acceptability in
field settings. In Thailand, numerous surveys among deployed
U.S. military personnel have shown that enteropathogenic
Campylobacter species,
Campylobacter jejuni and
C. coli, account for as many
as 60% of diarrheal cases (
2,
4,
8,
27,
30,
34,
42), a very
high prevalence compared to the prevalence detected in similar
studies conducted in other regions (
35). On the basis of this
observation, the pathogen-specific diagnostic tests used in
this study focused on
Campylobacter. This study of military
personnel presenting with acute diarrhea during deployment in
Thailand evaluated the clinical findings in concert with bedside
stool characterization and the results of field laboratory rapid
diagnostic tests as components of an overall diagnostic approach.
(This work was conducted in partial support of a doctoral thesis in public health at the Uniformed Services University, Bethesda, MD [D.R.T.].)

MATERIALS AND METHODS
Study population and enrollment criteria.
Annual U.S. military training exercises were conducted in the
Kingdom of Thailand in May 2000 and May 2001. Temporary medical
units for the evaluation and management of personnel were in
operation during the period of the exercise. Personnel presenting
with acute diarrhea were requested to volunteer for participation.
Enrollment criteria included the following: acute diarrhea duration
of

96 h, onset of illness

24 h after arrival in Thailand, illness
conforming to the definition of diarrhea, no antibiotic treatment
(with the exception of doxycycline, used for malaria prophylaxis)
in the previous 7 days, and the availability of a pretreatment
stool culture. Diarrhea was defined as three or more loose stools
in a 24-h period or two or more loose stools in a 24-h period
with one or more associated complaints, including abdominal
cramps, nausea, vomiting, or fever (oral temperature,

38°C).
Clinical evaluation and specimen collection.
A standardized questionnaire was used, and a medical examination was performed. The patients were asked to provide a stool specimen prior to administration of the first antibiotic dose. Stool characterization and bedside occult blood testing (Hemoccult; Beckman Coulter, Inc., Fullerton, CA) was completed by the study physician prior to transport of the specimen to the field laboratory. Stool specimens were graded on a scale from 1 to 5 (1, hard [normal]; 2, soft [normal]; 3, thick liquid; 4, opaque watery liquid; and 5, clear watery). Peripheral blood was collected directly into a Vacutainer tube containing EDTA (Beckton Dickinson Vacutainer Systems, Rutherford, NJ). Stool and blood specimens were transported to the field laboratory for immediate processing.
Stool microbiology (reference standard).
Primary plating of the stool specimens was undertaken at an on-site field laboratory, as described previously (38). Campylobacter species were isolated by a membrane filter method on nonselective blood agar before and after enrichment (39). Throughout this report, Campylobacter refers to both C. jejuni and C. coli. The isolates were transported to the Armed Forces Research Institute of Medical Sciences in Bangkok, Thailand, for species identification and susceptibility testing, as described previously (7, 9, 11). Five lactose-fermenting and five non-lactose-fermenting Escherichia coli colonies per specimen were tested by using DNA probes for the detection of enterotoxigenic E. coli (ETEC) toxins (heat-labile and heat-stable toxins), enteroinvasive E. coli(pMR17), enterohemorrhagic E. coli (Shiga-like toxin I and II producing), and enteropathogenic E. coli (eae and EAF plasmid positive) (10, 40). Microscopy evaluation of fresh stool specimens was used to evaluate the specimens for parasites. Aliquots of stool samples were frozen at –70°C on the day of receipt for viral antigen detection. The stool samples were evaluated for the presence of rotavirus and calicivirus antigens by a commercially available enzyme-linked immunosorbent assay (Rotazyme; Abbott Laboratories, North Chicago, IL) and a noncommercial antigen-capture calicivirus-specific enzyme-linked immunosorbent assay, respectively (26).
Diagnostic tests under evaluation (index tests).
Individuals performing the index tests were trained laboratory personnel masked to the results for the reference standard and clinical findings, with the exception of the results of the stool PCR assay, which was under development.
(i) Stool-based index tests.
All stool-based index tests were performed with fresh specimens on the day of receipt. Fecal leukocytes were semiquantitatively determined by examining methylene blue-stained fecal smears under a microscope. The numbers of fecal leukocytes present per high-power field were categorized as follows: none, rare, 1 to 5, 6 to 10, and >10. Fecal lactoferrin was detected with the commercial Leuko-Test kit (TechLab, Blacksburg, VA), according to the manufacturer's instructions. The presence of lactoferrin in a 1:50-diluted stool specimen was detected by a visually read positive agglutination of
1+, as defined by the manufacturer. The presence of C. jejuni or C. coli was detected by using the commercial ProSpecT Campylobacter microplate assay (Alexon-Trend, Inc., Ramsey, MN), according to the manufacturer's instructions. Campylobacter-specific antigens were detected by a visually read color development of
1+, as defined by the manufacturer. A multiplex PCR for the detection of C. jejuni and C. coli in the stool specimens was included during the first year of the exercise, as described previously (21). The PCR assay detects the ceuE genes in C. jejuni and C. coli and is useful for primary detection and species differentiation. DNA templates from 10% stool suspensions in TE (10 mM Tris-HCl, 1 mM disodium EDTA, pH 8.0) were prepared by silicon dioxide extraction (20, 21). Oligonucleotide primer sequences derived from the ceuE genes and the PCR amplification conditions have been reported previously (21). All PCR tests were conducted in the presence of appropriate controls, and the results were considered valid only if the results for the controls were proven to be accurate; i.e., positive controls were PCR positive and negative controls were PCR negative.
(ii) Blood-based index tests.
Blood samples were evaluated for plasma C-reactive protein (CRP), an acute-phase protein whose level is elevated during inflammatory disease, at the time of initial presentation to the clinic (32). Fresh plasma was evaluated semiquantitatively by using the commercial RapiTex CRP test (Dade Behring, Marburg, Germany), according to the manufacturer's instructions. Mononuclear cells (MNCs) were isolated by Ficoll-Hypaque density gradient analysis (Organon Teknika Corp., Durham, NC) and were cryopreserved in the field laboratory (3). Assays for antibody-secreting cells (ASCs) were performed at the Naval Medical Research Center, Silver Spring, MD, as described previously (3). Campylobacter-specific immunoglobulin A ASC responses were evaluated at the initial presentation and at the 72-h clinical follow-up by using the enzyme-linked immunospot assay methodology (3). The specific antigens used included a C. jejuni strain 81-176 glycine extract, C. jejuni strain 81-176 whole cells, and a common Thai C. jejuni strain (Lior 36) whole-cell lysate preparation (28). The numbers of spots found in comparable wells were summed and adjusted to the number per 106 MNCs. A positive ASC response was defined as five or more Campylobacter antigen-specific spots per 106 MNCs.
Statistical analysis.
The physician-performed bedside diagnostic assays (stool characterization and occult blood testing) and laboratory technician-performed rapid diagnostic assays (fecal leukocyte smear, lactoferrin latex agglutination assay, Campylobacter-specific enzyme immunoassay [EIA], and CRP test) were compared with the "gold standard" stool microbiology assay results. The performance characteristics of each assay were assessed. Test performance characteristics (sensitivity, specificity, predictive values, and likelihood ratios) were evaluated for each clinical finding (such as fever, abdominal cramps, and severe diarrhea) and diagnostic assay with 95% confidence intervals. The probability that a test result would be accurately rated as positive or negative was quantitated by using the area under the receiver operating characteristic curve (ROC) (16). In order to compare the areas under the ROC curves obtained from various diagnostic tests derived from the same cases, an adjustment was made to account for correlations between areas (17). The likelihood ratio was evaluated in context with pre- and posttest probabilities for different scenarios (low- versus high-prevalence region). In addition, clinical findings and diagnostic assays were evaluated singly and in series by using likelihood ratios in order to determine the most accurate and efficient diagnostic algorithm. The results of the patient surveys, symptom diaries, physician findings, and microbiological testing results were entered into EpiInfo software (version 6.04) databases. Statistical analysis was performed with SPSS for Windows (version 10.1). All tests were two tailed, and P values of <0.05 were considered statistically significant.

RESULTS
A total of 182 U.S. military personnel presenting with acute
diarrhea were enrolled in the study, and all individuals underwent
reference standard testing. All index tests were performed prior
to the administration of treatment and concurrent with the reference
standard testing, with the exception of testing for ASCs (as
described in Materials and Methods). The characteristics of
the study population are provided in Table
1. The cases enrolled
during the two exercise years had similar age and gender distributions.
A higher proportion of individuals received malaria prophylaxis
during the first exercise year; however, no difference in the
time to presentation with illness, the characteristics of the
illness, or the pathogen distribution was observed.
Campylobacter was identified in initial cultures of stools from 62% of all
cases, with 96% of the organisms found to be
C. jejuni and
C. coli accounting for the remainder.
Salmonella and
Plesiomonas were isolated from an additional 10 to 20% of the cases. The
high rates of isolation of invasive bacterial pathogens were
supported by the frequent clinical features of inflammatory
enteritis in >50% of the enrolled cases. A notable exception
to this pattern was the relatively low rate of positivity for
fecal leukocytes observed in the first exercise year. This observation
was not consistent with the results of concurrent fecal lactoferrin
testing, which was consistent between exercise years, and likely
represents variability in technician interpretation of fecal
leukocyte stains.
Clinical and laboratory findings were evaluated to assess their
potential as modalities for the detection of invasive enteropathogens,
as well as the diagnosis of
Campylobacter infection. The performance
characteristics of the tests for the prediction of invasive
enteropathogens are detailed in Table
2. In general, clinical
findings were not sensitive, with the exception of abdominal
cramping; however, this symptom had a specificity of less than
15%. Less frequent clinical findings, such as high-volume diarrhea,
gross blood in stools, documented fever at presentation, and
occult blood testing-positive stools, did yield greater specificities.
However, the overall accuracy of these findings, as represented
by the area under the ROC curve, was low (<0.65). The discordant
findings in the fecal leukocyte test results between exercise
years led to significant differences in test performance determination
(Table
2). Despite these differences, the fecal leukocyte test
sensitivity was less than 50% in both years. The lactoferrin
latex agglutination and plasma CRP tests provided reasonable
sensitivities but lacked specificity. Both tests yielded negative
likelihood ratios, amenable to ruling out the presence of an
invasive enteropathogen.
Clinical findings and bedside evaluation of the patient's stool
specimen were assessed for their ability to support a diagnosis
of
Campylobacter enteritis (Table
3). A relatively poor test
performance comparable to that seen for the other invasive enteropathogens
was observed. Given the predominance of
Campylobacter in this
case series, it is not surprising that the findings were similar.
Table
4 provides an assessment of the results of the field laboratory
tests for systemic or intestinal inflammation, as well as those
of the
Campylobacter-specific rapid diagnostic tests. Fecal
leukocyte determination and measurement of the circulating lymphocytes
producing antibodies against
Campylobacter-specific antigens
in the enzyme-linked immunospot assay produced poor results
in all measures of test performance. The lactoferrin latex agglutination
test demonstrated a high sensitivity and a negative predictive
value with a low specificity. The overall accuracy of this test
was comparable to that of the plasma CRP test.
The two stool-based
Campylobacter-specific tests, PCR and EIA,
yielded the highest specificities and positive likelihood ratios
of all tests under evaluation. More cases were evaluated by
EIA than by PCR, by which the stool specimens were evaluated
only in the second exercise year. False-negative results by
the PCR assay led to a lower sensitivity than that observed
for the EIA. A total of seven culture-positive
Campylobacter cases had negative results by the PCR test. The simultaneously
tested positive controls included for the detection of DNA in
the stool specimen were positive for all but one of the specimens,
ruling out the presence of nonspecific inhibitors as the primary
explanation for the false-negative results. Of these seven culture-positive,
PCR-negative specimens, three were also negative by the
Campylobacter-specific
EIA. The remaining four specimens had 4+ reactions by the EIA.
There were three culture-negative, PCR-positive specimens. Two
of these specimens were 4+ positive by the EIA. A total of six
culture-positive, EIA-negative specimens were observed. Follow-up
EIAs were undertaken for all of these cases by using stool specimens
collected either 3 or 7 days after the initial treatment. None
of the follow-up EIAs were positive, nor were any of the follow-up
stool cultures. Four culture-negative, EIA-positive specimens
were observed. Two of these cases had follow-up stool specimens
posttreatment in which one was culture negative and EIA negative
and the other was culture positive and EIA positive. Stool cultures
and EIAs performed 3 and 7 days after administration of the
first antibiotic dose detected no new EIA-positive cases. Among
the cases initially EIA positive, there continued to be positive
responses for 31% at day 3 and 23% at day 7. The semiquantitative
test results trended toward a high proportion of 3+ and 4+ results
in 80% of pretreatment specimens compared to 57% of posttreatment
specimens.

DISCUSSION
Rapid diagnostic tests range from the inexpensive Gram stain
for the presumptive identification of
Campylobacter spp. (sensitivity,
60 to 90%) to the more technically complex and more expensive
PCR (
1,
5,
19,
29,
31). The utility of a diagnostic test is
dependent upon the prevalence of the disease in the population.
In Fig.
1, the posttest probability of
Campylobacter-associated
illness is presented in various settings of endemicity and is
separated by the effect that a positive or a negative result
has on ruling in or ruling out a diagnosis of campylobacteriosis,
respectively. The presence of certain clinical features, including
gross blood in stools or documented fever at presentation, is
very specific (

93%) for
Campylobacter infection; however, this
diagnosis will be missed in 70 to 80% of cases. The inability
of the clinical presentation to guide therapy for individuals
with traveler's diarrhea was documented by Ericsson and coworkers
(
13). Reliance on specific yet insensitive clinical features
would lead to the withholding of therapy in individuals who
may benefit from early treatment. The ability of positive test
findings to alter the probability of the presence of
Campylobacter infection is most effective when a pathogen-specific stool-based
test, such as the EIA, is used. In a setting of hyperendemicity,
such as Thailand, with prevalence estimates of 50%, a positive
EIA result yields a 94% posttest probability of disease. Concurrent
findings of dysentery or fever further increase the posttest
probability of a positive EIA result to 98%. The impact of a
positive EIA result in a region with a lower prevalence of
Campylobacter is less dramatic. An estimated prevalence of 5%, as may be observed
in U.S. clinics, has a posttest probability of 46% in the event
of a positive EIA result. Unlike the setting in Thailand, bedside
clinical findings of dysentery or fever provide additive benefit
in increasing the probability to 72% in this setting.
The
Campylobacter-specific EIA has previously been evaluated
with frozen stool sample collections and in clinic-based series
in the United States and Europe (
6,
18,
41). Positive EIA results
have been documented out to 5 years from
Campylobacter-positive
stool specimens stored at –20°C, with a detection
threshold of 3
x 10
6 CFU/g of stool (
12). Real-time assessment
under routine conditions has documented a sensitivity of 89%
and a specificity of 98 to 99% in settings with a prevalence
of
Campylobacter ranging from 3 to 8% (
6,
18). The positive
likelihood ratio exceeded 30 and the negative likelihood ratio
was less than 0.15 in both previous evaluations. These findings
are comparable to the likelihood ratios observed in this study,
which is the first evaluation of this test under field conditions
and outside of an established hospital. The
ceuE-based multiplex
PCR evaluated in this study had previously been evaluated by
using frozen stool specimens, with comparisons of the culture
and PCR results based on microbiological recovery from stored
specimens (
21). The previous study documented much higher positivity
rates for PCR than for culture (77 and 56%, respectively). On
the basis of the test performance observed in this study with
fresh specimens, the earlier observation was likely due to the
presence of nonviable organisms in frozen specimens rather than
a significant difference in the sensitivities of the PCRs. The
rates of PCR false-negative results for fresh specimens observed
in this study were higher than those observed for the frozen
specimens in the previous study (
21) (18 and 8%, respectively).
This finding has been reported previously and in certain cases
has been postulated to be secondary to the presence in the specimen
of inhibitors that affect the PCR test (
25,
43). This may also
be explained by a PCR detection limit in the range of 10
5 campylobacters
per ml stool (
33), which may be higher than the detection limits
of culture methods. Further development of this test is needed
before it may gain clinical utility. The
Campylobacter-specific
ASC assay lacked test performance parameters supportive of its
clinical use. Potential improvements in this test may derive
from the use of more purified antigens that are broadly cross-reactive
with
Campylobacter species yet not cross-reactive with other
bacterial enteropathogens; however, the kinetics of the transient
circulation of these lymphocytes following mucosal infection
may limit the diagnostic potential of this test at the time
of clinical presentation (
14).
Rapid diagnostic tests based on the detection of an inflammatory state, blood-based CRP, and stool-based lactoferrin rather than on the detection of a specific pathogen were unable to increase the posttest probability beyond 75% in the event of a positive result (Fig. 1). However, the CRP and lactoferrin tests performed well at ruling out campylobacteriosis. A negative finding resulted in posttest probabilities of 14% for CRP and 7% for the lactoferrin assay (Fig. 1) in a setting of hyperendemicity, such as Thailand, which has a 50% prevalence (pretest probability). Given the improved ability to rule out Campylobacter infection and the infrequency with which blood specimens for the clinical management of diarrhea are obtained, the use of the fecal lactoferrin assay was preferable for screening for inflammatory enteritis. These findings are consistent with a systematic analysis of fecal screening tests (22). A meta-analysis stratified fecal screening test performance on the basis of the population studied, that is, populations from resource-poor regions and populations from developed countries, in order to account for differences in pathogen prevalence and disease spectrum (15). In developing countries, the rapid stool-based markers of inflammatory enteritis performed poorly in ruling in disease, possibly due to the high degree of endemicity of enteropathogens, asymptomatic carriage, frequent findings of inflammatory markers, and comorbid noninfectious conditions that may lead to positive findings, as postulated by the authors (15). The fecal lactoferrin assay has demonstrated value as a negative predictor of the presence of invasive enteropathogens in children in the developing world with acute diarrhea (23, 36), as was also shown in the deployed population in the present study. In this study, the fecal lactoferrin test would have failed to identify nine invasive pathogens (7%) or four Campylobacter cases (4%).
The regional predominance of Campylobacter previously documented in Thailand limits the broad application of these results across operational platforms in various regions. The results of the present study, coupled with analyses from an area where ETEC is predominant (with some contribution from Shigella species, which were not observed in this study), will better permit generalization. The Campylobacter-specific EIA provided desirable performance in ruling in or ruling out infection under field conditions, with results available within 2 h. Given the prevalence of Campylobacter in this setting and the high rates of fluoroquinolone resistance, this test most aids the clinician in determining the most appropriate type of patient management.

ACKNOWLEDGMENTS
We thank the technicians and staff of the Naval Medical Research
Center (Silver Spring, MD) and the Armed Forces Research Institute
of Medical Sciences (Bangkok, Thailand) for their microbiology
expertise and assistance with the conduct of the study. We also
thank the medical staff during the Cobra Gold exercises and
the voluntary participation of U.S. military personnel.
This work was supported by Work Unit number 643807A.849.D.A0002.
This study was approved by the ethical review committees of the Naval Medical Research Center (protocol 31528), the Walter Reed Army Institute of Research (WRAIR 792), and the Uniformed Services University of the Health Sciences (G187MT) and complies with all federal regulations governing the protection of human subjects.
The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the U.S. Department of Defense, or the U.S. government. D. Tribble is an employee of the U.S. government. This work was prepared as part of his official duties. Title 17 U.S.C. 101 defines U.S. government work as work prepared by a military service member or employee of the U.S. government as part of that person's official duties.

FOOTNOTES
* Corresponding author. Mailing address: Infectious Disease Clinical Research Program, Preventive Medicine & Biometrics Department, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814-5119. Phone: (301) 295-1422. Fax: (301) 295-1812. E-mail:
dtribble{at}usuhs.mil 
Published ahead of print on 30 January 2008. 

REFERENCES
1 - Amar, C. F., C. L. East, J. Gray, M. Iturriza-Gomara, E. A. Maclure, and J. McLauchlin. 2007. Detection by PCR of eight groups of enteric pathogens in 4,627 faecal samples: re-examination of the English case-control Infectious Intestinal Disease Study (1993-1996). Eur. J. Clin. Microbiol. Infect. Dis. 26:311-323.[CrossRef][Medline]
2 - Arthur, J. D., P. Echeverria, G. D. Shanks, J. Karwacki, L. Bodhidatta, and J. E. Brown. 1990. A comparative study of gastrointestinal infections in United States soldiers receiving doxycycline or mefloquine for malaria prophylaxis. Am. J. Trop. Med. Hyg. 43:608-613.[Abstract/Free Full Text]
3 - Baqar, S., A. A. Nour El Din, D. A. Scott, A. L. Bourgeois, A. S. Mourad, M. T. Kleinosky, M. J. Oplinger, and J. R. Murphy. 1997. Standardization of measurement of immunoglobulin-secreting cells in human peripheral circulation. Clin. Diagn. Lab. Immunol. 4:375-379.[Medline]
4 - Beecham, H. J., III, C. I. Lebron, and P. Echeverria. 1997. Short report: impact of traveler's diarrhea on United States troops deployed to Thailand. Am. J. Trop. Med. Hyg. 57:699-701.[Abstract/Free Full Text]
5 - Collins, E., M. Glennon, S. Hanley, A. M. Murray, M. Cormican, T. Smith, and M. Maher. 2001. Evaluation of a PCR/DNA probe colorimetric membrane assay for identification of Campylobacter spp. in human stool specimens. J. Clin. Microbiol. 39:4163-4165.[Abstract/Free Full Text]
6 - Dediste, A., O. Vandenberg, L. Vlaes, A. Ebraert, N. Douat, P. Bahwere, and J. P. Butzler. 2003. Evaluation of the ProSpecT microplate assay for detection of Campylobacter: a routine laboratory perspective. Clin. Microbiol. Infect. 9:1085-1090.[CrossRef][Medline]
7 - Echeverria, P., C. W. Hoge, L. Bodhidatta, C. Tungtaem, J. Herrmann, S. Imlarp, and K. Tamura. 1994. Etiology of diarrhea in a rural community in western Thailand: importance of enteric viruses and enterovirulent Escherichia coli. J. Infect. Dis. 169:916-919.[Medline]
8 - Echeverria, P., L. R. Jackson, C. W. Hoge, M. K. Arness, G. R. Dunnavant, and R. R. Larsen. 1993. Diarrhea in U.S. troops deployed to Thailand. J. Clin. Microbiol. 31:3351-3352.[Abstract/Free Full Text]
9 - Echeverria, P., O. Sethabutr, and C. Pitarangsi. 1991. Microbiology and diagnosis of infections with Shigella and enteroinvasive Escherichia coli. Rev. Infect. Dis. 13(Suppl. 4):S220-S225.[Medline]
10 - Echeverria, P., O. Sethabutr, and O. Serichantalergs. 1993. Modern diagnosis (with molecular tests) of acute infectious diarrhea. Gastroenterol. Clin. N. Am. 22:661-682.[Medline]
11 - Echeverria, P., D. N. Taylor, U. Lexsomboon, M. Bhaibulaya, N. R. Blacklow, K. Tamura, and R. Sakazaki. 1989. Case-control study of endemic diarrheal disease in Thai children. J. Infect. Dis. 159:543-548.[Medline]
12 - Endtz, H. P., C. W. Ang, N. van den Braak, A. Luijendijk, B. C. Jacobs, P. de Man, J. M. van Duin, A. van Belkum, and H. A. Verbrugh. 2000. Evaluation of a new commercial immunoassay for rapid detection of Campylobacter jejuni in stool samples. Eur. J. Clin. Microbiol. Infect. Dis. 19:794-797.[CrossRef][Medline]
13 - Ericsson, C. D., T. F. Patterson, and H. L. Dupont. 1987. Clinical presentation as a guide to therapy for travelers' diarrhea. Am. J. Med. Sci. 294:91-96.[Medline]
14 - Forrest, B. D. 1988. Identification of an intestinal immune response using peripheral blood lymphocytes. Lancet i:81-83.
15 - Gill, C. J., J. Lau, S. L. Gorbach, and D. H. Hamer. 2003. Diagnostic accuracy of stool assays for inflammatory bacterial gastroenteritis in developed and resource-poor countries. Clin. Infect. Dis. 37:365-375.[CrossRef][Medline]
16 - Hanley, J. A., and B. J. McNeil. 1982. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36.[Abstract/Free Full Text]
17 - Hanley, J. A., and B. J. McNeil. 1983. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-843.[Abstract/Free Full Text]
18 - Hindiyeh, M., S. Jense, S. Hohmann, H. Benett, C. Edwards, W. Aldeen, A. Croft, J. Daly, S. Mottice, and K. C. Carroll. 2000. Rapid detection of Campylobacter jejuni in stool specimens by an enzyme immunoassay and surveillance for Campylobacter upsaliensis in the greater Salt Lake City area. J. Clin. Microbiol. 38:3076-3079.[Abstract/Free Full Text]
19 - Ho, D. D., M. J. Ault, M. A. Ault, and G. H. Murata. 1982. Campylobacter enteritis: early diagnosis with Gram's stain. Arch. Intern. Med. 142:1858-1860.[Abstract/Free Full Text]
20 - Houng, H. S., O. Sethabutr, and P. Echeverria. 1997. A simple polymerase chain reaction technique to detect and differentiate Shigella and enteroinvasive Escherichia coli in human feces. Diagn. Microbiol. Infect. Dis. 28:19-25.[CrossRef][Medline]
21 - Houng, H. S., O. Sethabutr, W. Nirdnoy, D. E. Katz, and L. W. Pang. 2001. Development of a ceuE-based multiplex polymerase chain reaction (PCR) assay for direct detection and differentiation of Campylobacter jejuni and Campylobacter coli in Thailand. Diagn. Microbiol. Infect. Dis. 40:11-19.[CrossRef][Medline]
22 - Huicho, L., M. Campos, J. Rivera, and R. L. Guerrant. 1996. Fecal screening tests in the approach to acute infectious diarrhea: a scientific overview. Pediatr. Infect. Dis. J. 15:486-494.[CrossRef][Medline]
23 - Huicho, L., V. Garaycochea, N. Uchima, R. Zerpa, and R. L. Guerrant. 1997. Fecal lactoferrin, fecal leukocytes and occult blood in the diagnostic approach to childhood invasive diarrhea. Pediatr. Infect. Dis. J. 16:644-647.[CrossRef][Medline]
24 - Hyams, K. C., A. L. Bourgeois, B. R. Merrell, P. Rozmajzl, J. Escamilla, S. A. Thornton, G. M. Wasserman, A. Burke, P. Echeverria, K. Y. Green, et al. 1991. Diarrheal disease during Operation Desert Shield. N. Engl. J. Med. 325:1423-1428.[Abstract]
25 - Iijima, Y., N. T. Asako, M. Aihara, and K. Hayashi. 2004. Improvement in the detection rate of diarrhoeagenic bacteria in human stool specimens by a rapid real-time PCR assay. J. Med. Microbiol. 53:617-622.[Abstract/Free Full Text]
26 - Jiang, X., N. Wilton, W. M. Zhong, T. Farkas, P. W. Huang, E. Barrett, M. Guerrero, G. Ruiz-Palacios, K. Y. Green, J. Green, A. D. Hale, M. K. Estes, L. K. Pickering, and D. O. Matson. 2000. Diagnosis of human caliciviruses by use of enzyme immunoassays. J. Infect. Dis. 181(Suppl. 2):S349-S359.[CrossRef][Medline]
27 - Kuschner, R. A., A. F. Trofa, R. J. Thomas, C. W. Hoge, C. Pitarangsi, S. Amato, R. P. Olafson, P. Echeverria, J. C. Sadoff, and D. N. Taylor. 1995. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin. Infect. Dis. 21:536-541.[Medline]
28 - Loeb, M. R., A. L. Zachary, and D. H. Smith. 1981. Isolation and partial characterization of outer and inner membranes from encapsulated Haemophilus influenzae type b. J. Bacteriol. 145:596-604.[Abstract/Free Full Text]
29 - Mahendru, M., K. N. Prasad, T. N. Dhole, and A. Ayyagari. 1997. Rapid identification of Campylobacter jejuni strains by polymerase chain reaction & their restriction fragment length polymorphism analysis. Indian J. Med. Res. 105:9-14.[Medline]
30 - Murphy, G. S., Jr., P. Echeverria, L. R. Jackson, M. K. Arness, C. LeBron, and C. Pitarangsi. 1996. Ciprofloxacin- and azithromycin-resistant Campylobacter causing traveler's diarrhea in U.S. troops deployed to Thailand in 1994. Clin. Infect. Dis. 22:868-869.[Medline]
31 - Oyofo, B. A., S. A. Thornton, D. H. Burr, T. J. Trust, O. R. Pavlovskis, and P. Guerry. 1992. Specific detection of Campylobacter jejuni and Campylobacter coli by using polymerase chain reaction. J. Clin. Microbiol. 30:2613-2619.[Abstract/Free Full Text]
32 - Pepys, M. B. 1981. C-reactive protein fifty years on. Lancet i:653-657.
33 - Persson, S., and K. E. Olsen. 2005. Multiplex PCR for identification of Campylobacter coli and Campylobacter jejuni from pure cultures and directly on stool samples. J. Med. Microbiol. 54:1043-1047.[Abstract/Free Full Text]
34 - Petruccelli, B. P., G. S. Murphy, J. L. Sanchez, S. Walz, R. DeFraites, J. Gelnett, R. L. Haberberger, P. Echeverria, and D. N. Taylor. 1992. Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J. Infect. Dis. 165:557-560.[Medline]
35 - Riddle, M. S., J. W. Sanders, S. D. Putnam, and D. R. Tribble. 2006. Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. Am. J. Trop. Med. Hyg. 74:891-900.[Abstract/Free Full Text]
36 - Ruiz-Pelaez, J. G., and S. Mattar. 1999. Accuracy of fecal lactoferrin and other stool tests for diagnosis of invasive diarrhea at a Colombian pediatric hospital. Pediatr. Infect. Dis. J. 18:342-346.[CrossRef][Medline]
37 - Sanchez, J. L., J. Gelnett, B. P. Petruccelli, R. F. Defraites, and D. N. Taylor. 1998. Diarrheal disease incidence and morbidity among United States military personnel during short-term missions overseas. Am. J. Trop. Med. Hyg. 58:299-304.[Abstract]
38 - Sanders, J. W., D. W. Isenbarger, S. E. Walz, L. W. Pang, D. A. Scott, C. Tamminga, B. A. Oyofo, W. C. Hewitson, J. L. Sanchez, C. Pitarangsi, P. Echeverria, and D. R. Tribble. 2002. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am. J. Trop. Med. Hyg. 67:533-538.[Abstract]
39 - Steele, T. W., and S. N. McDermott. 1984. The use of membrane filters applied directly to the surface of agar plates for the isolation of Campylobacter jejuni from feces. Pathology 16:263-265.[Medline]
40 - Taylor, D. N., P. Echeverria, O. Sethabutr, C. Pitarangsi, U. Leksomboon, N. R. Blacklow, B. Rowe, R. Gross, and J. Cross. 1988. Clinical and microbiologic features of Shigella and enteroinvasive Escherichia coli infections detected by DNA hybridization. J. Clin. Microbiol. 26:1362-1366.[Abstract/Free Full Text]
41 - Tolcin, R., M. M. LaSalvia, B. A. Kirkley, E. A. Vetter, F. R. Cockerill, III, and G. W. Procop. 2000. Evaluation of the Alexon-trend ProSpecT Campylobacter microplate assay. J. Clin. Microbiol. 38:3853-3855.[Abstract/Free Full Text]
42 - Tribble, D. R., J. W. Sanders, L. W. Pang, C. Mason, C. Pitarangsi, S. Baqar, A. Armstrong, P. Hshieh, A. Fox, E. A. Maley, C. Lebron, D. J. Faix, J. V. Lawler, G. Nayak, M. Lewis, L. Bodhidatta, and D. A. Scott. 2007. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin. Infect. Dis. 44:338-346.[CrossRef][Medline]
43 - Wilson, I. G. 1997. Inhibition and facilitation of nucleic acid amplification. Appl. Environ. Microbiol. 63:3741-3751.[Medline]
Journal of Clinical Microbiology, April 2008, p. 1418-1425, Vol. 46, No. 4
0095-1137/08/$08.00+0 doi:10.1128/JCM.02168-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.